Comparison of Spectrum Pharmaceuticals Inc. (SPPI) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) – MS Wkly

Since Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership of both companies.

Valuation & Earnings

Table 1 highlights Spectrum Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows the return on equity, net margins and return on assets of the two firms.

Risk and Volatility

Spectrum Pharmaceuticals Inc. is 154.00% more volatile than Standard and Poors 500 due to its 2.54 beta. Competitively, Brainstorm Cell Therapeutics Inc.s beta is 1.19 which is 19.00% more volatile than Standard and Poors 500.

Analyst Ratings

The following table given below contains the ratings and recommendations for Spectrum Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.

The upside potential is 400.00% for Spectrum Pharmaceuticals Inc. with average target price of $41. Meanwhile, Brainstorm Cell Therapeutics Inc.s average target price is $9, while its potential upside is 131.96%. The data from earlier shows that analysts view suggest that Spectrum Pharmaceuticals Inc. seems more appealing than Brainstorm Cell Therapeutics Inc.

Institutional and Insider Ownership

Roughly 75.6% of Spectrum Pharmaceuticals Inc. shares are held by institutional investors while 11.4% of Brainstorm Cell Therapeutics Inc. are owned by institutional investors. Spectrum Pharmaceuticals Inc.s share held by insiders are 1.3%. Competitively, insiders own roughly 0.6% of Brainstorm Cell Therapeutics Inc.s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Spectrum Pharmaceuticals Inc. has -13.37% weaker performance while Brainstorm Cell Therapeutics Inc. has 12.96% stronger performance.

Summary

Spectrum Pharmaceuticals Inc. beats Brainstorm Cell Therapeutics Inc. on 8 of the 10 factors.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkins lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More:
Comparison of Spectrum Pharmaceuticals Inc. (SPPI) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly